Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections

Vaccine

Volumn 30, Issue 51, 2012, Pages 7374-7380

  Böttcher Friebertshäuser, Eva ^a   Lu, Yinghui ^a   Meyer, Daniela ^a   Sielaff, Frank ^a   Steinmetzer, Torsten ^a   Klenk, Hans Dieter ^a   Garten, Wolfgang ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Hemagglutinin; Influenza; Peptide mimetic protease inhibitors; Proteolytic activation; TMPRSS2

Indexed keywords

ANTIVIRUS AGENT; BENZYLSULFONYL DEXTRO ARGININE PROLINE 4 AMIDINOBENZYLAMIDE; HUMAN AIRWAY TRYPSIN LIKE PROTEASE; OSELTAMIVIR; PROTEINASE; TRANSMEMBRANE PROTEASE SERINE S1 MEMBER 2; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLUENZA A; INFLUENZA B; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RESPIRATORY EPITHELIUM; VIROGENESIS; VIRUS DETECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; DIPEPTIDES; EPITHELIAL CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; PROTEASE INHIBITORS; SERINE ENDOPEPTIDASES; SULFONAMIDES; VIRUS ATTACHMENT;

EID: 84870250521     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.001     Document Type: Article

References (32)

1. Ascenzi P., Bocedi A., Bolognesi M., Spallarossa A., Coletta M., De Cristofaro R., et al. The bovine basic pancreatic trypsin inhibitor (Kunitz inhibitor): a milestone protein. Curr Protein Pept Sci 2003, 4:231-251. (review).
2. Böttcher E., Matrosovich T., Beyerle M., Klenk H.D., Garten W., Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol 2006, 80:9896-9898.
3. Böttcher E., Freuer C., Steinmetzer T., Klenk H.D., Garten W. MDCK cells that express proteases TMPRSS2 and HAT provide a cell system to propagate influenza viruses in the absence of trypsin and to study cleavage of HA and its inhibition. Vaccine 2009, 27:6324-6329.
4. Böttcher-Friebertshäuser E., Freuer C., Sielaff F., Schmidt S., Eickmann M., Uhlendorff J., et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol 2010, 84:5605-5614.
5. Böttcher-Friebertshäuser E., Stein D.A., Klenk H.D., Garten W. Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. J Virol 2011, 85:1554-1562.
6. Chaipan C., Kobasa D., Bertram S., Glowacka I., Steffen I., Tsegaye T.S., et al. Proteolytic activation of the 1918 influenza virus hemagglutinin. J Virol 2009, 83:3200-3211.
7. Duval X., van der Werf S., Blanchon T., Mosnier A., Bouscambert-Duchamp M., Tibi A., et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010, 7:e1000362.
8. Gamblin S.J., Skehel J.J. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010, 285:28403-28409. (review).
9. Garten W., Klenk H.D. Cleavage activation of the influenza virus hemagglutinin and its role in pathogenesis. Avian Influenza: Monographs in Virology 2008, 27.
10. Govorkova E.A., Webster R.G. Combination chemotherapy for influenza. Viruses 2010, 2:1510-1529.
11. Hallenberger S., Bosch V., Angliker H., Shaw E., Klenk H.D., Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992, 360:358-361.
12. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 2009, 15:155-162.
13. Hellstern P., Stürzebecher U., Wuchold B., Haubelt H., Seyfert U.T., Bauer M., et al. Preservation of in vitro function of platelets stored in the presence of a synthetic dual inhibitor of factor Xa and thrombin. J Thromb Haemost 2007, 5:2119-2126.
14. Horimoto T., Nakayama K., Smeekens S.P., Kawaoka Y. Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J Virol 1994, 68:6074-6078.
15. Ilyushina N.A., Bovin N.V., Webster R.G., Govorkova E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006, 70:121-131.
16. Kim T.S., Heinlein C., Hackman R.C., Nelson P.S. Phenotypic analysis of mice lacking the Tmprss2-encoded protease. Mol Cell Biol 2006, 26:965-975.
17. Klenk H.D., Rott R., Orlich M., Blödorn J. Activation of influenza A viruses by trypsin treatment. Virology 1975, 68:426-439.
18. Lazarowitz S.G., Choppin P.W. Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 1975, 68:440-454.
19. Matrosovich M., Matrosovich T., Garten W., Klenk H.D. New low-viscosity overlay medium for viral plaque assays. Virol J 2006, 3:63.
20. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78:12665-12667.
21. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.
22. RKI. Seasonal report 2010/11. http://influenza.rki.de/Saisonberichte/2010.pdf.
23. Sales K.U., Hobson J.P., Wagenaar-Miller R., Szabo R., Rasmussen A.L., Bey A., et al. Expression and genetic loss of function analysis of the HAT/DESC cluster proteases TMPRSS11A and HAT. PLoS One 2011, 6:e23261.
24. Sielaff F., Böttcher-Friebertshäuser E., Meyer D., Saupe S.M., Volk I.M., Garten W., et al. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorg Med Chem Lett 2011, 214860-214864.
25. Sisay M.T., Steinmetzer T., Stirnberg M., Maurer E., Hammami M., Bajorath J., et al. Identification of the first low-molecular-weight inhibitors of matriptase-2. J Med Chem 2010, 53:5523-5535.
26. Stech J., Garn H., Wegmann M., Wagner R., Klenk H.D. A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin. Nat Med 2005, 11:683-689.
27. Steinhauer D.A. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999, 258:1-20. Review.
28. Stieneke-Gröber A., Vey M., Angliker H., Shaw E., Thomas G., Roberts C., et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992, 11:2407-2414.
29. WHO Weekly epidemiological record. No. 45, 86; 2011. p. 497-508.
30. Zhirnov O.P., Matrosovich T.Y., Matrosovich M.N., Klenk H.D. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir Chem Chemother 2011, 21:169-174.
31. Zhirnov O.P., Ovcharenko A.V., Bukrinskaya A.G. Suppression of influenza virus replication in infected mice by protease inhibitors. J Gen Virol 1984, 65:191-196.
32. Zhirnov O.P. High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination. J Med Virol 1987, 21:161-167.